Near East University and University of Sharjah Researchers Present Innovative Study on Pregnancy-Induced Hypertension at DUPHAT 2025
Dr. Dilber Uzun Ozsahin, from the Department of Medical Diagnostic Imaging at the College of Health Sciences, Research Group Coordinator of Operational Research and Integrated Artificial Intelligence in Healthcare at the Research Institute for Medical and Health Sciences, University of Sharjah, UAE, and Director of the Operational Research Center in Healthcare at Near East University, Turkey, presented significant research findings on treatments for pregnancy-induced hypertension at the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT 2025). The presentation took place at the Dubai World Trade Center, United Arab Emirates, on January 8, 2025. The research, conducted by an international team of researchers from Near East University (Turkey), University of Sharjah (UAE), focused on evaluating FDA-approved pharmacological treatments for pregnancy-induced hypertension (PIH), a condition that can lead to severe complications for both mothers and fetuses. Using advanced fuzzy PROMETHEE methodology, the study ranked five FDA-approved treatments for PIH, considering both patient and hospital preferences. The analysis revealed hydralazine as the top choice from the patient perspective, while nicardipine ranked highest from the hospital standpoint. These findings aim to enhance clinical standards and improve patient care in PIH treatment.
"This innovative approach integrates both patient and hospital perspectives, paving the way for more personalized PIH treatment strategies," stated Dr. Ozsahin.
The collaborative research team comprised Dr. Natacha Usanase from Near East University, Dr. Dilber Uzun Ozsahin from University of Sharjah and Near East University, Dr. Leena R. David from University of Sharjah and Manipal College of Health Professions, and Dr. Berna Uzun and Dr. Ilker Ozsahin from Near East University. Their research findings aim to support healthcare practitioners in making well-informed decisions about PIH treatment, leading to enhanced clinical outcomes and patient care standards.
